6. Cardiometabolic and Musculoskeletal Health at Menopause
Pedagogy: This lesson uses fracture-risk stratification — teaching clinicians to assess, prevent, and treat menopause-related bone loss using FRAX, DEXA, and the evidence base for HRT and bone-specific agents.
Learning Objectives
- Quantify accelerated bone loss in early postmenopause: ~2% annually for 5-10 years
- Apply FRAX assessment and identify when DEXA scanning is indicated
- Describe HRT as first-line PREVENTION of menopause-related bone loss
- Outline bone-specific agents for established osteoporosis: bisphosphonates, denosumab, teriparatide
Key Facts
Bone Loss at Menopause
Women experience approximately 2% annual bone mass loss starting 1-3 years before menopause, lasting 5-10 years, resulting in a 10-15% average reduction in BMD. HRT is first-line for prevention of menopause-related bone loss and significantly reduces fragility fracture risk (NICE: fracture risk decreases from 60/1,000 to 40/1,000 over 5 years) (1,2).
Assessment
FRAX score: Calculate for all postmenopausal women with risk factors. DEXA scan: If FRAX indicates intermediate risk, or if clinical risk factors suggest osteoporosis (fragility fracture, prolonged steroid use, POI, low BMI). NICE recommends considering HRT for bone protection in women without VMS who are under 60 and within 10 years of menopause (2).
Treatment Hierarchy
| Level | Agent | Indication |
|---|---|---|
| Prevention | HRT | First-line for menopause-related bone loss prevention; benefits maintained during treatment |
| Treatment (high risk) | Bisphosphonates (alendronate, risedronate) or denosumab | Established osteoporosis or high FRAX score |
| Treatment (very high risk) | Teriparatide, romosozumab | Bone-anabolic agents for severe osteoporosis |
Important: Denosumab cessation causes accelerated bone loss and increased fracture risk — mandatory transition to bisphosphonate on stopping. HRT bone benefits decrease after stopping; consider bisphosphonate transition in high-risk women (1,2).
Sarcopenia
Loss of muscle strength, mass, and physical function is more prevalent in postmenopausal women. Assess for sarcopenia alongside osteoporosis. Resistance training is the primary intervention (2).
Clinical Pearl HRT is first-line for PREVENTION of menopause-related bone loss — not for treatment of established osteoporosis. Know the distinction: prevention (HRT) vs treatment (bisphosphonates/denosumab).
Clinical Pearl Denosumab cessation triggers rebound bone loss and fracture risk. NEVER stop denosumab without transitioning to a bisphosphonate. This is a critical safety point.
Case-Based Examples
Case 1: 56-year-old stopping HRT — bone protection plan
Presentation: A 56-year-old has been on HRT for 5 years and wishes to stop. She has no osteoporosis risk factors. FRAX has not been calculated.
Question: What bone protection assessment should you perform?
Model Answer: Before stopping HRT: calculate FRAX score (with or without BMD). If FRAX indicates low risk: stop HRT with lifestyle advice (weight-bearing exercise, calcium 1000mg/day, vitamin D, falls prevention). If intermediate risk: DEXA scan. If DEXA shows osteopenia/osteoporosis: discuss bisphosphonate before/upon stopping HRT, as bone protection decreases after cessation. Review at 2 years post-cessation. For all women: ensure adequate vitamin D (10-20mcg/day) and calcium.
Case 2: 62-year-old with fragility fracture on long-term HRT
Presentation: A 62-year-old on HRT for 11 years sustains a Colles fracture after a fall from standing height. DEXA: T-score -2.8 at lumbar spine.
Question: How does her management change?
Model Answer: Fragility fracture + T-score -2.8 = established osteoporosis. HRT alone is insufficient — she needs bone-specific treatment. First-line: oral bisphosphonate (alendronate 70mg weekly or risedronate 35mg weekly). Alternatively: denosumab 60mg 6-monthly (if bisphosphonate not tolerated/contraindicated — but plan for transition if stopped). Ensure: calcium 1000mg/day + vitamin D, falls risk assessment, resistance exercise. She may choose to continue HRT for menopausal symptoms alongside the bisphosphonate. Repeat DEXA in 3 years to monitor treatment response.
Self-Assessment Questions
PLAB/MLA HRT and fracture risk
NICE data show fragility fracture risk decreases from 60/1,000 to approximately what with 5 years HRT use?
A. 55/1,000
B. 40/1,000
C. 20/1,000
D. No change
Answer: B. NICE NG23: fracture risk decreases from 60/1,000 to 40/1,000 over 5 years of HRT use.
MRCGP Denosumab cessation safety
A woman wishes to stop denosumab after 3 years. What is the critical safety consideration?
A. No special precautions needed
B. Must transition to a bisphosphonate — cessation causes accelerated bone loss and increased fracture risk
C. Switch to calcium supplements only
D. Denosumab cannot be stopped once started
Answer: B. Denosumab cessation causes rebound bone loss (vertebral fracture risk increases significantly). Mandatory transition to bisphosphonate upon stopping.
Professor HRT vs bisphosphonates for fracture prevention
Compare the evidence quality for HRT vs bisphosphonates in fracture prevention.
A. Both have identical RCT evidence
B. WHI provides RCT evidence for HRT fracture prevention but the population was not selected for osteoporosis; bisphosphonate trials (FIT, VERT, HIP) specifically enrolled women with osteoporosis or prior fracture — making direct comparison inappropriate
C. Bisphosphonates have no RCT evidence
D. HRT is superior to bisphosphonates for established osteoporosis
Answer: B. WHI demonstrated significant fracture reduction with HRT, but enrolled unselected women (not osteoporosis-specific). Bisphosphonate landmark trials enrolled women with low BMD or prior fracture, demonstrating 40-70% vertebral fracture reduction. The populations differ, making head-to-head comparison impossible. Guideline position: HRT for prevention; bisphosphonates/denosumab for established osteoporosis.
Take-Away Messages
- ~2% annual bone loss for 5-10 years around menopause; 10-15% average BMD reduction
- HRT is first-line for PREVENTION of menopause-related bone loss (NICE: fracture risk 60 to 40/1,000 over 5 years)
- Calculate FRAX for all postmenopausal women with risk factors; DEXA if intermediate risk
- Bisphosphonates/denosumab for established osteoporosis; teriparatide/romosozumab for very high risk
- Denosumab cessation: MANDATORY bisphosphonate transition — rebound bone loss is a critical safety issue